Project Grant K99CA290052
- This federal Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $112,230.00 to The University of Texas MD Anderson Cancer Center to conduct research on the role of gut microbiome dysbiosis in the development and progression of lung adenocarcinoma (LUAD), the most common type of non-small cell lung cancer. The key objectives of this 2.5-year project are to: 1) Determine how gut microbiome dysbiosis impacts immunomodulation and inflammation...
- This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research at Stanford University to investigate how the human gut microbiome can be modulated to enhance immune responses against cancer, with a focus on improving the efficacy of cancer immunotherapy treatments. The $179,988 award, which runs from January 1, 2025 to December 31, 2026, aims to identify bacterial genes and functions that can boost the body's immune response to immune...
- This federal Project Grant award of $606,839.00, provided by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), supports research to identify gut microbiota that actively deplete intestinal amino acids and evaluate how they affect the tumor microenvironment and cancer progression. The primary awardee is Weill Medical College of Cornell University, a leading academic medical institution with expertise in biomedical research and translational science. The project aims to...
- This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $426,425 to Baylor College of Medicine to conduct a pilot study examining the relationship between gut microbiome composition, metabolic dysfunction-associated steatotic liver disease (MASLD), and hepatocellular carcinoma (HCC). The key objectives of this 2-year study are to: 1) characterize baseline gut microbiome diversity associated with MASLD with and without HCC, 2)...
- This $627,422 Project Grant award from the National Cancer Institute under the Cancer Treatment Research (CFDA 93.395) program supports research by the Regents of the University of Michigan to engineer commensal bacteria that can neutralize the colibactin genotoxin produced by certain gut bacteria associated with increased colorectal cancer risk. The key products and services to be delivered under this 5-year grant include: 1) Further optimization of the surface display of the anti-toxin...
- This Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) totaling $638,120 provides funding to The Trustees of Columbia University in the City of New York to conduct research aimed at improving the therapeutic efficacy and safety of microbial neoantigen vaccines for cancer treatment. The key objectives are to: 1) explore how bacterial localization within tumors affects immune responses and therapeutic outcomes, 2) investigate how bacterial...
- This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower program) provides $154,642 to the Sloan-Kettering Institute for Cancer Research in New York to conduct research on identifying conserved cancer-specific immunopeptide targets in metastatic colorectal cancer. The project aims to systematically elucidate the evolving immunopeptidome (peptides presented by HLA class I molecules) from patient-derived colorectal cancer organoids to reveal targetable...
- This federal Project Grant award of $400,890.00 from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) aims to profile patient-specific tumor-microbiome interactions and conduct quantitative molecular analyses to elucidate microbiome-mediated modulation of immune checkpoint molecules in mismatch repair-proficient, microsatellite-stable colorectal tumors. The goal is to provide a strategic roadmap and personalized workflow to enhance immunotherapeutic effects on non-responsive...
- This Project Grant award, provided by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), focuses on exploring the role of bacterial-derived small molecules in improving immunotherapy response rates and overall survival for non-small cell lung cancer patients. The $540,288 award to the University of Florida aims to test the central hypothesis that specific bacteria produce small molecules that can augment the efficacy and mitigate the toxicity of immune...
- This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $157,980.00 in funding to Dr. Jonathan Rennhack at the Loyola University of Chicago Health Sciences Campus to support research on the role of microenvironmental chemokines in beta-catenin/TCF signaling and gene occupancy during colorectal cancer metastasis to the liver and lung. The key objectives of this research project are to leverage molecular techniques, patient-derived organoids,...
DEFINING NOVEL MECHANISMS OF MICROBIOTA IN REGULATING ANTI-TUMOR RESPONSES - PROJECT SUMMARY/ABSTRACT RESEARCH: CANCER IS THE SECOND LEADING CAUSE OF MORTALITY IN THE WORLD, WITH ESTIMATES AS HIGH AS 1.9 MILLION NEW DIAGNOSES AND 0.6 MILLION DEATHS IN THE UNITED STATES LAST YEAR. TRILLIONS OF NORMALLY BENEFICIAL MICROBES, TERMED THE MICROBIOTA, CONTINUOUSLY COLONIZE THE MAMMALIAN INTESTINE AND EMERGING EVIDENCE INDICATES KEY ROLES FOR THESE MICROBES IN IMPACTING CANCER. THIS INCLUDES BOTH PROMOTING TUMOR GROWTH AND PROGRESSION, BUT ALSO IN SUPPORTING RESPONSE TO IMMUNOTHERAPIES, RAISING THE EXCITING POSSIBILITY TO MANIPULATE MICROBIOTA TO COMBAT CANCER, HOWEVER THE MECHANISMS BY WHICH MICROBIOTA INFLUENCE CANCER PROGRESSION AND IMMUNOTHERAPIES REMAIN POORLY UNDERSTOOD. BASED ON MY PUBLISHED AND NEW PRELIMINARY DATA, I HYPOTHESIZE THAT HOST-MICROBIOTA INTERACTIONS (I) PROMOTE TUMOR GROWTH BY LIMITING METABOLITES THAT PROVOKE ANTI-TUMOR IMMUNITY, AND (II) SHAPE SYSTEMIC ANTI-TUMOR IMMUNITY AND THE OUTCOME OF IMMUNOTHERAPY BY ANTIGEN-SPECIFIC RESPONSES TO GUT MICROBIOTA VIA CROSSTALK OF RORGT+ LYMPHOCYTES. THESE STUDIES WILL DEFINE TWO NOVEL PATHWAYS BY WHICH MICROBIOTA INTERACTS WITH MAMMALIAN HOSTS TO IMPACT TUMOR GROWTH, PROGRESSION, AND IMMUNOTHERAPY RESPONSE, THUS PROVOKING NOVEL OPPORTUNITIES FOR INTERVENTION. CAREER GOALS: MY OVERARCHING GOAL IS TO BECOME AN INDEPENDENT INVESTIGATOR AT AN ACADEMIC INSTITUTION WHERE I INVESTIGATE THE MECHANISMS BY WHICH HOST-MICROBE INTERACTIONS MODULATE ANTI-TUMOR IMMUNITY AND IMMUNOTHERAPY RESPONSE FOR THE TREATMENT OF CANCER. FURTHER, I ASPIRE TO BECOME AN INSPIRATIONAL AND PRODUCTIVE MENTOR AS THESE ARE ESSENTIAL ASPECTS OF BEING AN INDEPENDENT INVESTIGATOR. CAREER DEVELOPMENT PLAN: TO BECOME A SUCCESSFUL INDEPENDENT INVESTIGATOR, I WILL FURTHER DEVELOP A VARIOUS RESEARCH, PROFESSIONAL, AND PERSONAL SKILLS. THESE WILL INCLUDE FURTHER ACQUIRING EXPERTISE IN CANCER BIOLOGY AND MICROBIOLOGY TECHNIQUES, AS WELL AS FOSTERING COLLABORATIONS AND DEVELOPING SKILLS IN WRITING, COMMUNICATING, TEACHING, MENTORING AND LABORATORY MANAGEMENT. MY HOST LABORATORY AND WEILL CORNELL MEDICINE PROVIDE AN OUTSTANDING ACADEMIC ENVIRONMENT WHERE TRAINEES CAN FULFIL THESE CRITERIA BY FOSTERING SCIENTIFIC COLLABORATION AND ENROLLING IN COURSES TO DEVELOP SKILLS IN SPECIALIST SCIENTIFIC AREAS, PERSONAL DEVELOPMENT, AND LABORATORY MANAGEMENT. THE MENTORSHIP I WILL RECEIVE WILL BE OF THE HIGHEST STANDARD. FURTHER, IN ADDITION TO MY MENTOR AND CO-MENTOR, I HAVE SUPPORT FROM A TEAM OF INDEPENDENT INVESTIGATORS WITH EXTENSIVE EXPERTISE IN AREAS THAT WILL GREATLY FACILITATE THE COMPLETION OF EXPERIMENTS PROPOSED AND MY CAREER TRANSITION INTO INDEPENDENCE. CAREER DEVELOPMENT ENVIRONMENT: I WILL PERFORM THE K99 PHASE IN THE LABORATORY OF DR. GREGORY SONNENBERG AT WEILL CORNELL MEDICINE, WHICH PROVIDES AN OUTSTANDING ENVIRONMENT IN TERMS OF THE RESOURCES AND FACILITIES AVAILABLE. WEILL CORNELL MEDICINE IS AN IDEAL ENVIRONMENT TO DEVELOP DURING THE K99 PHASE AS I PROGRESS TO BECOME A SUCCESSFUL INDEPENDENT INVESTIGATOR. THE LABORATORY HAS ACCESS TO ALL THE INSTRUMENTS AND FACILITIES NECESSARY TO COMPLETE THE EXPERIMENTS PROPOSED IN THIS APPLICATION.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $138.2k | 7/2/25 | ||
| Not listed | $138.2k | 6/20/24 |